DIPLOMA IN PHARMACEUTICAL MEDICINE EXAMINATION

Part 1 – 16th September 2015
Part 2 – 19th October 2015

HAMILTON HOUSE CONFERENCE CENTRE, LONDON*

*Please note that the Faculty of Pharmaceutical Medicine reserves the right to change the venue in the event of unforeseen circumstances.

The fee for the 2015 Part 1 examination is £315.00 and the fee for the Part 2 examination is £535.

Candidates can apply for Part 1 only, Part 2 only (only if they have already passed Part 1) or Parts 1 and 2 together. Only candidates that are successful in Part 1 will be permitted to take Part 2.

Registration for the exam is made online via the Faculty website.

Please note that if you wish to apply for one or both parts of this year's examination, the online application must be made by the closing date of Monday 3rd August 2015. It is in your interest to apply well before the closing date to ensure that any problems with your application can be resolved.

Please note that an examination candidate who withdraws from the examination must do so in writing. Fees will be refunded to a candidate whose withdrawal reaches the Faculty office before the closing date. A handling fee of £50.00 will be charged to candidates who withdraw between the closing date and the date of the examination. A candidate who does not appear for the examination or withdraws after commencing the examination will not be entitled to a refund.

The Board of Examiners is often asked to provide clearer guidance as to the standard expected of candidates’ answers. Please indicate on your application form if you authorise the Board of Examiners to use your written answers for purposes of illustration. Any answers used will be anonymised by typing the text and removing any reference to candidate number.

The Faculty of Pharmaceutical Medicine processes the personal data which you enter on your application form in connection with the operation and administration of the Diploma in Pharmaceutical Medicine examination. A list of the names of successful candidates is published after the examination and also posted on the Faculty website.

Past papers for the Short Answer Question papers of the examination for the last four years and the Critical Appraisal Question from 2012 to 2014 are available free as PDF files on the Faculty website:

https://www.fpm.org.uk/trainingexams/exams/dpm_past_papers

We are unable to supply copies of past Multiple-Choice Question papers but some examples are provided. A sample MCQ answer sheet is also provided.
The Syllabus for Pharmaceutical Medicine

Adoption of PharmaTrain 2010 Syllabus by FPM

Since 1976 the Syllabus for Pharmaceutical Medicine has been developed by the Royal Colleges of Physicians in the UK for the Diploma in Pharmaceutical Medicine examination, and as the basis for course curricula in postgraduate training in the discipline, and subsequently specialty, of pharmaceutical medicine. Over the years the Syllabus underwent a number of revisions and updates under the auspices of the Colleges, and since 1989 by the Faculty of Pharmaceutical Medicine. In 1985 the Faculty's Syllabus for Pharmaceutical Medicine was offered to IFAPP as the basis for the IFAPP Syllabus for Pharmaceutical Medicine, utilised for course curricula and examinations in Europe and by IFAPP National Member Associations around the world. In similar vein, in 2009 the Syllabus for Pharmaceutical Medicine was offered by the Faculty to IMI PharmaTrain, along with, we understand, the current IFAPP Syllabus, as the basis for PharmaTrain's International Syllabus for Pharmaceutical Medicine, recognising the requirement for update, review and revision for widespread harmonised, international use under the PharmaTrain banner (presented as PharmaTrain Syllabus 2010).

Given the provenance of The Syllabus for Pharmaceutical Medicine summarised above, the Faculty is pleased to receive the PharmaTrain Syllabus 2010 as the updated and revised Syllabus for Pharmaceutical Medicine. As a public partner of IMI PharmaTrain, the Faculty recognises that PharmaTrain Syllabus 2010 carries the brand of ‘PharmaTrain’. The Faculty also recognises, and welcomes, the opportunity afforded by PharmaTrain for, in future, systematic, collective and harmonised review & revision of this international Syllabus, and agrees to abide by the requirements and conditions established for this, and to which the Faculty will assuredly contribute.

The syllabus is divided into sections covering the following:

<table>
<thead>
<tr>
<th>SECTION</th>
<th>Topic</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Discovery of Medicines</td>
</tr>
<tr>
<td>2</td>
<td>Development of Medicines: Planning</td>
</tr>
<tr>
<td>3</td>
<td>Non-Clinical Testing</td>
</tr>
<tr>
<td>4</td>
<td>Pharmaceutical Development</td>
</tr>
<tr>
<td>5</td>
<td>Exploratory Development (Molecule to Proof-of-Concept)</td>
</tr>
<tr>
<td>6</td>
<td>Confirmatory Development: Strategies</td>
</tr>
<tr>
<td>7</td>
<td>Clinical Trials</td>
</tr>
<tr>
<td>8</td>
<td>Ethics and Legal Issues</td>
</tr>
<tr>
<td>9</td>
<td>Data Management and Statistics</td>
</tr>
<tr>
<td>10</td>
<td>Regulatory Affairs</td>
</tr>
<tr>
<td>11</td>
<td>Drug Safety, Pharmacovigilance and Pharmacoepidemiology</td>
</tr>
<tr>
<td>12</td>
<td>Information, Promotion and Education</td>
</tr>
<tr>
<td>13</td>
<td>Economics of Healthcare</td>
</tr>
<tr>
<td>14</td>
<td>Therapeutics</td>
</tr>
</tbody>
</table>
Please see the enclosed full syllabus included in this pack.

FACULTY OF PHARMACEUTICAL MEDICINE

OF THE ROYAL COLLEGES OF PHYSICIANS OF THE UNITED KINGDOM

Diploma in Pharmaceutical Medicine (Parts 1 and 2)

GUIDANCE FOR CANDIDATES AND SUPERVISORS

EXAMINATION REGULATIONS AND PROCEDURES

APRIL 2014

Faculty of Pharmaceutical Medicine
3rd Floor, 30 Furnival Street
London, EC4A 1JQ
Tel: +44 (0)20 7831 7662, Fax: +44 (0)20 7831 3513
Email: fpm@fpm.org.uk, Website: www.fpm.org.uk

Registered Charity No 1130573 and Company No 6870644
SECTION ONE: GUIDANCE NOTES FOR CANDIDATES AND SUPERVISORS FOR THE DIPLOMA IN PHARMACEUTICAL MEDICINE (PARTS 1 and 2)

Preface
These notes are intended to provide guidance to physicians studying for the Diploma in Pharmaceutical Medicine (candidates). It is hoped that these notes will clarify the requirements and avoid misunderstandings, thereby enabling candidates to prepare themselves adequately and efficiently. These guidance notes should be read in conjunction with the Syllabus for Pharmaceutical Medicine and the Examination Specification, both of which are available on the Faculty website and enclosed in the examination pack, along with the Examination Regulations and Procedures in Section Two.

Introduction
From 1976, the three UK Royal Colleges of Physicians awarded the Diploma in Pharmaceutical Medicine. In 1994, five years after the creation of the Faculty, responsibility for the Diploma examination was transferred to the Faculty which has continued to be responsible for it ever since.

From its inception until 2012 the Diploma was a single examination comprising several different papers, all of which had to be passed at the same time to achieve an overall pass. In 2013 the structure of the Diploma changed such that it is now a two-part examination, the parts of which have to be passed sequentially.

The examination is intended to test knowledge and its application relating to all parts of the Syllabus, though more weight is given to those areas for which a pharmaceutical physician is likely to be responsible or which have a direct impact on the physician’s decision making.

In terms of career progression, passing the examination indicates that the individual has reached a certain level of achievement. Possession of the Diploma allows pharmaceutical physicians to apply for Membership of the Faculty of Pharmaceutical Medicine (MFPM). For those pursuing a Certificate of Completion of Training (CCT) or Certificate of Eligibility for Specialist Registration (CESR) in the specialty of Pharmaceutical Medicine in the UK, success in the examination (or a recognised equivalent examination) is a requirement for completion of Pharmaceutical Medicine Specialty Training (PMST).

Each part is held once a year.

Eligibility
The Diploma examination is open to doctors who have entered pharmaceutical medicine and received structured training in the discipline.

Eligibility of candidates to sit the Diploma examination will be assessed at the time of registration for Part 1 of the examination. The criteria are given in the Examination Regulations and Procedures in Section 2 of this booklet and are explained below. Where there is doubt, prospective candidates, particularly those from outside the UK, are encouraged to seek advice from the Faculty early in their preparation for the examination, rather than at the time of submitting their application to sit the examination.

The Faculty admits only medical graduates to sit the Diploma examination. In this regard, it accepts undergraduate training that leads to the award of a medical
qualification recognised by the General Medical Council (GMC) in the UK. All candidates must be registered as medical practitioners.

The Faculty also strongly recommends that a candidate completes full-time training in pharmaceutical medicine for at least two years at the time of sitting Part 1 of the Diploma examination, whether or not the candidate is enrolled in PMST. This experience is best acquired within the pharmaceutical industry, in a contract research organisation or in a drug regulatory authority. Time spent in research within an academic department of a medical school or hospital is rarely appropriate.

Applicants for Membership of the Faculty or for specialty registration are reminded that they must meet additional eligibility requirements. Success in the Diploma examination is necessary but not sufficient.

**Educational Supervisor**

Candidates who are undertaking PMST must have an Educational Supervisor to help them prepare for the Diploma examination. Whilst other candidates for the Diploma examination are not required to have an Educational Supervisor, it is strongly recommended that they do so. Educational Supervisors should meet the criteria that have been set for Educational Supervisors in Pharmaceutical Medicine Specialty Training. These are available on the Faculty’s website.

It is sensible for the Educational Supervisor to be employed in the same organisation and / or the same locality as the candidate. This aids communication, facilitates a one-to-one teacher-pupil relationship, enables the candidate to gain access to personnel and information of relevance to their training and preparation for the examination and helps the candidate obtain the necessary time and resources for their training. If the candidate and their line manager cannot identify an appropriate supervisor within their organisation or locally, the Faculty may be asked to assist in finding a supervisor.

The role of an Educational Supervisor is important. The supervisor should assist in devising the training of a novice pharmaceutical physician, taking into account his or her earlier postgraduate training and past experience. A programme can be outlined to remedy deficiencies in exposure to particular areas of the syllabus. Attendance at training courses, congresses or symposia, provision of CPD teach-in material, distance learning and secondment to other departments of the company or to an external institution may all be considered. The programme should be tailored to the individual’s needs and will take into account his or her likely career development. Thereafter, the supervisor should monitor the programme, helping to identify other needs that come to light and how they can be met. The supervisor should also assist the trainee by suggesting reading material, discussing recent developments in pharmaceutical medicine and issues often not covered in textbooks, and providing feedback on practice examination questions.

**Preparation for the Examination**

A Diploma candidate should plan a training programme in pharmaceutical medicine, where appropriate with the advice of his or her Educational Supervisor. The training in pharmaceutical medicine should involve courses, distance-learning packages, other tuition and personal study.

Candidates are not required to have attended a postgraduate course covering the syllabus for pharmaceutical medicine, though most do. There are many such courses currently being run in Europe including several in the UK. In addition, several courses cover specific areas that fall within the syllabus.
Personal study should supplement other approaches to learning. Study of a current edition of one of the published comprehensive texts is highly recommended as preparation for the examination. Textbooks on key topics in the syllabus such as clinical trials, pharmacokinetics, medical statistics, safety assessments, etc, are also essential reading. Regulatory guidelines, particularly those issued by ICH, can also be a valuable source of up-to-date information.

Candidates are advised to study past Short Answer Question and Critical Appraisal papers, which are available from the Faculty office at no charge, though, as with all examinations, they should not be taken as an absolute guide to future examinations. It is particularly helpful to practice answering past questions under conditions mimicking the examination and obtain feedback from an Educational Supervisor or compare one's answer with those of colleagues. Past MCQ examination papers are not available to candidates as some questions may be used again.

A valuable exercise by way of preparation for the Critical Appraisal Paper is to undertake critical review of published clinical pharmacology studies, larger clinical trials and epidemiological studies. Making a detailed record of one's views about the Methods and Results before reading the Discussion section makes the process active rather than just accepting the views of the authors. It is particularly useful to critique a paper that forms the subject of an accompanying editorial, again completing the exercise before reading the editorial, which serves as feedback. Comparison of one's responses with those of a colleague can add great value to this exercise.

In addition to reviewing published papers, much can be gained by spending time with colleagues working in different areas of the industry. Like any other medical specialty, pharmaceutical medicine is learned through examples in practice.

The examination tests knowledge and its application relating to ALL parts of the syllabus and, in aggregate, a combination of these approaches to preparation must cover all elements of the syllabus. However, some sections are given greater emphasis in the examination and, therefore, require more study. More weight is given to those areas for which a pharmaceutical physician is likely to be responsible such as the management and reporting of issues related to drug safety. Knowledge of both principles and practice of therapeutics is considered an essential requirement for pharmaceutical physicians and is included in the examination.

**Format of the Examination**

The examination is prepared by panels of examiners and the Officers of the Board of Examiners. Core features of the answers and the allocation of marks are also prepared before the examination and distributed for guidance to examiners when the scripts are marked.

The Diploma is a two-part examination. Part 1 consists of a multiple choice question (MCQ) paper and Part 2 comprises a Short Answer Question paper and a Critical Appraisal paper. The two parts of the exam are set on two separate days approximately 4 weeks apart.

Part 1 consists of an MCQ paper of 375 questions (75 stems each with 5 completions) all to be completed in 2 hours 30 minutes;
Part 2 consists of:
- a Short Answer Question paper of ten questions all to be completed in 2 hours 30 minutes;
- a Critical Appraisal paper in which candidates have 2 hours 30 minutes to study a published paper and answer questions on it.

The time allowed for the written examination is sufficient to complete the papers working at a reasonable pace.

Candidates may apply to sit both Parts 1 and 2 at the same time but only candidates that achieve a Pass in the Part 1 exam will be allowed to sit the Part 2 exam.

A Pass in the Part 1 exam will be valid for a maximum of four attempts at the Part 2 examination. If a candidate does not pass the Part 2 exam after four attempts then the Part 1 pass will become invalid and the candidate will be required to re-sit Part 1.

MCQ Paper
Each MCQ has a stem followed by five completions, any number of which may be true. The candidate is required to identify which are ‘true’ and which are ‘false’. Each correct response earns one mark (maximum of 375 marks overall), no response receives zero marks and an incorrect answer receives zero marks.

Short Answer Question Paper
The questions in the Short Answer Question paper can test either discrete pieces of knowledge, or can bring together several issues and subsections of the syllabus. The candidate is expected to identify the major relevant points and thereby show their understanding of the topic. Candidates should read each question carefully and answer the question asked. Each answer should be written in note or bullet point form. In total, 10 marks are available for each question (100 marks for the full paper). Candidates should note any guidance provided on the distribution of marks within a question and, if a question consists of more than one part, take care to answer every part.

It is important to attempt every question since 10% of the possible marks will be lost for each question not answered. Candidates who do not attempt or fail to score on three or more questions will fail this paper (and hence the whole examination) whatever their aggregate score is on the remainder of the paper.

Critical Appraisal Paper
The Critical Appraisal Paper is designed to test the ability of candidates to summarise and criticise the important components of work published in a scientific paper of direct relevance to the role of a pharmaceutical physician. Candidates are given 2 hours 30 minutes to review the paper and answer the questions on it. Each answer should be written in note or bullet point form.

Some questions will test understanding of the paper such as subject selection criteria, study design, analysis and results. Others will focus on discussing the merits of the chosen design and analysis and how it could have been improved, the interpretation and relevance of the results for clinical practice, and suggestions for further research. Candidates are not expected to have detailed knowledge of the therapeutic area that was studied.

The question paper will include information on the distribution of available marks, with more marks being allocated to challenging the trial and re-design sections.
Candidates should note this information and ensure that they allocate their time appropriately.

**General**

*It is emphasised that no credit is given in any part of the examination for irrelevant information or discussion of topics outside the scope of the question. Where a question has more than one part, all parts must be answered to gain maximum marks. Marks may be deducted for important errors of commission, particularly if they relate to statements of unsafe and/or unethical actions. Answers must be legible and the meaning clear; however, poor spelling or grammar are not penalised.*

**Assessments**

Standards for the written papers are set using an objective criterion-referenced procedure to determine the pass mark. The procedure takes into account the difficulty of the paper and the standard expected of candidates at Diploma level. There is no limit to the number of candidates who may pass.

The *MCQ* paper is marked by computer.

Each question in the *Short Answer* and *Critical Appraisal* papers is marked independently by at least two examiners using the core features of the answer and guide to allocation of marks provided. Each question is marked by the same examiners for all candidates to maximise standardisation unless the number of candidates or other factors make this unfeasible. A moderating procedure exists for any individual questions for which a discrepancy arises in the marks awarded. Throughout the examination process candidates are identified by their candidate numbers only.

**Adjudication**

A meeting of the Officers and Panel Convenors of the Board of Examiners is held to adjudicate after each of the two parts of the examination.

Adjudication takes place within approximately 2 weeks after the Part 1 examination. Candidates will be notified of the outcome immediately afterwards.

Adjudication of the Part 2 examination takes place approximately 2 weeks prior to a full meeting of the Board to award grades for each part of the written examination. The performance of all candidates in both papers is examined carefully, but particular attention is paid to candidates who are close to the boundary between pass and fail in one or other of the two papers.

The final decision on ‘Pass’ or ‘Fail’ is made at an adjudication meeting of the full Board of Examiners held about six to eight weeks after the examination. Candidates are identified by their candidate numbers only throughout the examination until after the adjudication.

Candidates must achieve a pass grade in the MCQ paper to Pass the Part 1 examination, and a pass grade in both the short answer and critical appraisal papers to pass Part 2.

The Board of Examiners will award the Diploma to candidates who have passed both Part 1 and Part 2, and may award the Diploma with Distinction to candidates who obtain consistently high marks in the examination.
After completion of the adjudication, a detailed review of the overall results and of the examination procedures is conducted. Re-marking of written examination papers after completion of the moderation and adjudication processes will only be undertaken at the request of the Appeals Panel in response to a well-founded appeal.
SECTION TWO: EXAMINATION REGULATIONS AND PROCEDURES

Diploma Examination
A.1 The Diploma in Pharmaceutical Medicine (Dip Pharm Med) is awarded by the Faculty on the recommendation of the Board of Examiners.
A.2 A Diploma Examination is conducted annually by the Board of Examiners at fixed times and places announced by the Faculty.
A.3 There are two parts to the Diploma examination; Part 1 and Part 2.
A.4 Candidates must pass Part 1 before being eligible to sit Part 2. A pass in Part 1 is valid for a maximum of four attempts at Part 2. If a candidate fails to pass Part 2 in this time then s/he must re-sit and pass Part 1.
A.5 The two parts of the examination must be passed for a candidate to be awarded the Diploma.
A.6 The Diploma candidate is required to sit two written examinations.
A.7 A candidate will, ordinarily, not be permitted to sit either Part of the Diploma in Pharmaceutical Medicine on more than six (6) occasions.
A.8 Membership of the Faculty may be granted to pharmaceutical physicians who possess the Diploma, meet other eligibility criteria, and have their application approved by the Board of the Faculty (see A.44).
A.9 The Faculty will provide a Diploma Examination pack containing all necessary forms with Guidance Notes for Candidates and Supervisors, Syllabus for Pharmaceutical Medicine, Examination Specification and the Examination Regulations and Procedures.

Eligibility of Candidates
A.10 Eligibility of candidates to sit the Diploma examination will be decided by the Board of Examiners.
A.11 Candidates must possess a medical qualification recognised by the General Medical Council (GMC) in the UK and be included on an appropriate medical register.
A.12 Eligibility will be determined when a candidate applies to sit the Part 1 examination.
A.13 Candidates must inform the Faculty if there has any change in their status that might affect their eligibility at the time of submitting an application to sit Part 2.

Diploma Registration
A.14 Candidates must complete the online application form and submit payment by the announced closing date.
A.15 Candidates may submit a combined application to sit both Part 1 and Part 2 in the same year. The fee for Part 2 for candidates who are unsuccessful in Part 1 will be refunded.
A.16 When attending an examination, candidates are required to provide photographic identity (passport, driving licence or ID from place of work) at registration on each day.
A.17 When submitting the application for Part 1, candidates must provide evidence of registration as a medical practitioner by provision of their GMC registration number. Candidates not registered in the United Kingdom should provide the original or a notarised (legally validated) copy and translation of their medical registration certificate. If this does not show current registration then a certificate of good standing will also need to be produced.
Educational Supervisor
A.18 Candidates who are enrolled with the Faculty and Joint Royal Colleges of Physicians Training Board (JRCPTB) for Pharmaceutical Medicine Specialty Training must have an Educational Supervisor to assist in planning their training in pharmaceutical medicine. In addition, a Senior Specialty Adviser will be allocated to these candidates. It is recommended that candidates who are not enrolling for Pharmaceutical Medicine Specialty Training also have an Educational Supervisor.

A.19 It is recommended that a Diploma candidate should have completed, by the time of the Part 1 Diploma Examination, at least two years in a post that provides practical experience and training in pharmaceutical medicine.

Syllabus
A.20 The Syllabus for Pharmaceutical Medicine is presented in detail on the Faculty’s website and is enclosed in the examination pack.

A.21 A Diploma candidate should expect questions during the examination on all sections of the syllabus. A guide to the approximate distribution of questions is provided in the Examination Specification. The discipline of pharmaceutical medicine is ever evolving and a Diploma candidate should be aware of important recent changes and current issues.

Examination
A.22 The examination is held as two parts and each part is held on one day. There will be an interval of approximately 4 weeks between the Part 1 and Part 2 examination days in any given year. The places and times are available from the Faculty about 10 months before the examination and are advertised about 3 months before the closing date for registration.

A.23 Part 1 of the examination comprises a single Multiple Choice Question (MCQ) paper. All 375 questions (75 stems each with 5 completions) should be answered in 2 hours 30 minutes.

A.24 Part 2 of the examination comprises two separate written papers: Short Answer Question paper. All ten questions should be answered in 2 hours 30 minutes.

A.25 Critical Appraisal paper. Candidates will be given 2 hours 30 minutes to study the set published paper and to answer questions on it.

A.26 The final selection of questions for the examination papers is made by the Officers and Panel Convenors of the Board of Examiners. The Board ensures that the examination as a whole covers the syllabus appropriately. Core features of the short answers and critical appraisal papers are checked and agreed.

A.27 Candidates will be given a time of arrival and finishing on each examination day. These might be earlier than the start of the first written paper and/or later than the finish of the second paper. Candidates will be supervised under examination conditions until the finishing time on each day. Any candidate that arrives late will not be admitted to the examination.

A.28 Candidates will not be allowed to leave the room within the first 15 minutes of any written paper and candidates arriving late will not be admitted after this time. Any candidate wishing to leave and return to the examination hall will be accompanied.

A.28 Mobile phones, calculators and other electronic devices may not be used during the examination and, if brought into the examination hall, must be switched off and placed to the side of the room out of sight of all candidates.
Assessment
A.29 The multiple-choice questions are marked by computer and grades are then assigned according to pre-set standards. An anomaly monitoring system (AMS) may be used to detect instances of copying or collusion by looking for anomalous patterns of responses by candidates, the answers of one candidate being more similar to those of another candidate than would be expected by chance alone.
A.30 Each question in the Short Answer and Critical Appraisal papers is marked independently by at least two examiners. Individual questions will be marked by the same examiners acting independently for all candidates unless the number of candidates or other factors make this unfeasible. A moderating procedure exists for any individual questions for which a discrepancy arises in the marks awarded.

Adjudication
A.31 A meeting of the Officers and Panel Convenors of the Board of Examiners is held to adjudicate after each of the two parts of the examination.
A.32 Adjudication takes place within approximately 2 weeks after the Part 1 examination. Candidates will be notified of the outcome immediately afterwards.
A.33 Adjudication of the Part 2 examination takes place approximately 2 weeks prior to a full meeting of the Board to award grades for each of the papers that constitute Part 2. The performance of all candidates in both papers is examined carefully, but particular attention is paid to candidates who are close to the boundary between pass and fail in one or other of the two papers.
A.34 The final decision on pass or fail for the Part 2 examination, and for the award of the Diploma, is made at an adjudication meeting of the full Board of Examiners held about six to eight weeks after the Part 2 examination.
A.35 Each paper is assessed as either a pass or fail. A pass is required in the MCQ paper for a candidate to pass Part 1, and a pass in both the short answer and critical appraisal papers is required for a candidate to pass Part 2.
A.36 Candidates are identified by their candidate numbers only throughout the examination until after the adjudication.
A.37 The Board of Examiners may award the Diploma with Distinction to a candidate who has consistently high marks in all three papers.

Communication of Results
A.38 The Faculty will advise all candidates of the outcome in writing. Unsuccessful candidates will receive a written summary of their performance in the different sections of the Syllabus.
A.39 Candidates will be informed of the outcome of the Part 1 examination immediately after the adjudication meeting. This takes place approximately 2 weeks after the day of the examination.
A.40 Candidates will be informed of the outcome of the Part 2 examination immediately after the Board of Examiners full meeting. This takes place approximately 8 weeks after the day of the Part 2 examination.
A.41 A Diploma certificate will be provided as appropriate.
A.42 Candidates are not entitled to the return of their answer papers after the examination. Written papers will only be re-marked after the adjudication at the request of the Appeals Panel in response to a well-founded appeal. The Board Of Examiners cannot enter into detailed discussion with a candidate but will try to be as constructive as possible in any correspondence.
A.43 An unsuccessful candidate may re-sit the Diploma Examination up to five times.

Membership of the Faculty
A.44 A pharmaceutical physician who has been awarded the Diploma in Pharmaceutical Medicine, meets other eligibility criteria and wishes to become a Member of the Faculty must complete an application form and submit it to the Faculty office.

Fees
A.45 The Faculty will maintain a schedule of fees, which will be included in the Diploma Examination pack with the conditions that apply clearly stated.
A.46 Separate fees are levied for the Part 1 and Part 2 examinations. Candidates who apply to sit both parts in the same year and who are unsuccessful in Part 1 will have the fee for Part 2 returned.

Conduct
A.47 The Faculty may refuse to register a person as a Diploma candidate and may withdraw such registration at any time if the candidate's behaviour is prejudicial before or during the examination by not complying with examination regulations or instructions.
A.48 The Faculty will investigate any suspected dishonesty or misconduct by a candidate in relation to the Diploma Examination and, if appropriate, revoke the Diploma and Membership.
A.49 Any candidate who wishes account to be taken of exceptional circumstances or conditions present BEFORE the start of the examination that may affect his or her performance must refer to the Policy for Candidates with Special Requirements, details of which are available on the Faculty website or from the Faculty office. Such circumstances must be notified to the Chair of the Board of Examiners or the Examinations Administrator BEFORE SITTING the examination; such information passed to the Faculty after sitting the examination cannot be taken into account. This information will be kept confidential.
A.50 Any candidate who wishes account to be taken of exceptional conditions or circumstances arising AFTER THE START of the examination must make the invigilator / examiners aware of such circumstances AT THE TIME of the examination AND make representation in writing as described in the Appeals Procedure. Information provided after the day of the examination shall not be taken into account.
A.51 The Appeals Procedure should also be followed for any representations by candidates on the conduct of the Diploma Examination. Details are available on the Faculty website or from the Faculty office.

The Faculty of Pharmaceutical Medicine is committed to promoting equal opportunity and eliminating discrimination in all areas of its activity